NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
复制标题
DOI：
10.1186/1476-511x-9-29
复制
发表时间：
2010-03-11
影响因子：
4.5
通讯作者：
Nakamuta, Makoto
中科院分区：
文献类型：
--
作者：
Enjoji, Munechika;Machida, Kazuyuki;Nakamuta, Makoto
背景资料：我们最近检查了非酒精性脂肪性肝病（NAFLD）患者的腹部脂肪分布、饮食摄入和生化数据，发现非肥胖NAFLD患者不一定表现出胰岛素抵抗和/或脂肪细胞因子分泌失调。然而，饮食中的胆固醇摄入过多的非肥胖患者与肥胖患者相比，虽然总能量和碳水化合物的摄入量并不过量。因此，过量的胆固醇摄入似乎是与NAFLD的发展和肝injure.Methods的主要因素之一：我们回顾了一年的随访数据的非肥胖NAFLD患者治疗尼曼-匹克C1样1抑制剂依折麦布，以评估其治疗效果的临床参数相关的NAFLD。8例患者接受10 mg/天依折麦布治疗，未进行任何饮食或运动调整。8例患者中有4例患者最初接受依折麦布给药。在其余4例患者中，药物从熊去氧胆酸转换为依折麦布。结果：在观察期间，每例患者的体重指数均维持在25 kg/m2以下。血清ALT水平在6个月内显著下降，4例患者的水平达到正常范围（
Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury.Methods: We reviewed a year of follow-up data of non-obese NAFLD patients treated with Niemann-Pick C1 like 1 inhibitor ezetimibe to evaluate its therapeutic effect on clinical parameters related to NAFLD. Without any dietary or exercise modification, 10 mg/day of ezetimibe was given to 8 patients. In 4 of 8 patients, ezetimibe was administered initially. In the remaining 4 patients, medication was switched from ursodeoxycholic acid to ezetimibe.Results: In each patient, body mass index was maintained under 25 kg/m(2) during the observation period. Serum ALT levels significantly decreased within 6 months and in 4 patients levels reached the normal range (